What it's sold for
- Weight loss
- Blood sugar control
What has actually been tested
- Obesity
- Overweight
- Type 2 Diabetes
- Diabetes Mellitus, Type 2
- Obesity & Overweight
- Healthy
- Type 2 Diabetes Mellitus
- Obesity and Obesity-related Medical Conditions
Is it studied for what it's sold for?
Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.
Studied
Weight loss
Studied
Blood sugar control
Every trial on record
Every registered human study we can find for Tirzepatide. Click any ID to read the original record — we would rather you checked us than trusted us.
| Trial ID | Title | Condition | Phase | Status | Enrolled |
|---|---|---|---|---|---|
| NCT07701460 | Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1 | Weight Maintenance | Not phased | Not yet recruiting | 200 |
| NCT07728812 | Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy | Obesity & Overweight | Not phased | Not yet recruiting | 424 |
| NCT07179120 | Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health | Obesity-related Male Infertility | Phase 2 | Not yet recruiting | 180 |
| NCT06939088 | Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder | Alcohol Use Disorder, Alcohol Abuse/Dependence | Phase 2 | Recruiting now | 108 |
| NCT06820281 | Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Type 1 Diabetes Mellitus | Phase 2 | Not yet recruiting | 44 |
| NCT06143956 | A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Obesity, Overweight | Phase 2 | Recruiting now | 1481 |
| NCT07671391 | A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants | Obesity Adult Onset | Phase 2 | Not yet recruiting | 60 |
| NCT07245771 | Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity | Obesity &Amp; Overweight | Phase 2 | Recruiting now | 104 |
| NCT06517212 | Tirzepatide Weight Loss for MRD+ Early Breast Cancer | Breast Cancer, Breast Neoplasms | Phase 2 | Recruiting now | 48 |
| NCT06937203 | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Obesity, Diabetes Mellitus, Type 2 | Phase 2 | Recruiting now | 150 |
| NCT07176663 | Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure | Obesity | Not phased | Not yet recruiting | 15 |
| NCT06976853 | Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | Crohn Disease (CD) | Phase 2 | Recruiting now | 60 |
| NCT07589322 | Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | Obesity and Metabolic Syndrome | Not phased | Recruiting now | 120 |
| NCT07609160 | Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals | Obesity, Sarcopenia | Not phased | Not yet recruiting | 108 |
| NCT07573163 | Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion | Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status | Phase 2 | Not yet recruiting | 34 |
| NCT06606821 | The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease | Coronary Artery Disease, Coronary Microvascular Dysfunction | Phase 4 | Recruiting now | 124 |
| NCT07265752 | Tirzepatide for the Treatment of Cannabis Use Disorder | Cannabis Use Disorder | Phase 2 | Not yet recruiting | 6 |
| NCT07527910 | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 2 | Recruiting now | 204 |
| NCT06885736 | LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy | Obesity | Not phased | Recruiting now | 232 |
| NCT06864026 | A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Psoriatic Arthritis, Overweight or Obesity | Phase 4 | Recruiting now | 200 |
| NCT06897475 | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Type 2 Diabetes | Phase 2 | Recruiting now | 240 |
| NCT06994338 | Tirzepatide for Alcohol Use Disorder | Alcohol Use Disorder, Obesity and Overweight | Phase 2 | Recruiting now | 42 |
| NCT06439277 | A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Obesity, Weight Gain | Phase 3 | Recruiting now | 300 |
| NCT06811324 | Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults | Obesity Prevention, Sarcopenia in Elderly | Phase 2 | Recruiting now | 20 |
| NCT05708859 | Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT | Type II Diabetes, Atherosclerosis | Phase 4 | Recruiting now | 120 |
| NCT06934642 | Effect of Tirzepatide on Markers of MASLD in Patients With Obesity | MASLD, Obesity | Phase 1 | Recruiting now | 8 |
| NCT07554638 | Incretin Therapies in Obesity-related HFpEF | Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction | Phase 4 | Not yet recruiting | 50 |
| NCT07095517 | Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors | Colorectal Cancer Prevention, Colorectal Adenoma | Phase 1 | Recruiting now | 20 |
| NCT07630454 | Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF | Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 4 | Not yet recruiting | 602 |
| NCT07228741 | Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity | Acute Lymphoblastic Leukemia, Obesity | Phase 2 | Recruiting now | 20 |
| NCT07557355 | A Study of SRSD384 in Overweight or Obese Participants | Overweight , Obesity | Phase 2 | Not yet recruiting | 78 |
| NCT06937099 | Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Crohn's Disease, Obesity or Overweight | Phase 3 | Recruiting now | 290 |
| NCT06191848 | Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) | Obesity, Knee Osteoarthritis | Phase 4 | Recruiting now | 352 |
| NCT07298915 | The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | Obesity & Overweight | Phase 3 | Not yet recruiting | 24 |
| NCT07223242 | Tailored Exercise Training Study Among Adults With HFpEF | HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies | Phase 3 | Recruiting now | 120 |
| NCT07706088 | Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy | Neuropathy, Small Fiber, Diabete Mellitus | Phase 4 | Not yet recruiting | 40 |
| NCT06246799 | Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes | Type 2 Diabetes (Adult Onset) | Phase 3 | Recruiting now | 256 |
| NCT06734273 | Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss | Obesity and Obesity-related Medical Conditions | Phase 1 | Recruiting now | 42 |
| NCT07046819 | Tirzepatide in MetALD | Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder | Phase 2 | Recruiting now | 120 |
| NCT05553093 | Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 4 | Recruiting now | 150 |
| NCT07247084 | A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) | Obesity | Phase 4 | Recruiting now | 3000 |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | Endometrial Cancer, Endometrial Intraepithelial Neoplasia | Phase 2 | Not yet recruiting | 40 |
| NCT07700030 | High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE) | Weight Loss | Not phased | Not yet recruiting | 32 |
| NCT07521631 | Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Obesity | Phase 2 | Recruiting now | 372 |
| NCT07468552 | Trial of Tirzepatide for the Treatment of Cannabis Use Disorder | Cannabis Use Disorder | Phase 2 | Not yet recruiting | 100 |
| NCT06651177 | Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Opioid Use Disorder, Opioid Use Disorder, Moderate | Phase 2 | Recruiting now | 310 |
| NCT06774079 | Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients | Crohn Disease | Phase 4 | Recruiting now | 24 |
| NCT07671248 | Tirzepatide in the Treatment of Cannabis Use Disorder | Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe | Phase 3 | Not yet recruiting | 15 |
| NCT07536516 | Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients | Diabetes Mellitus | Not phased | Recruiting now | 20 |
| NCT07457437 | Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment | Muscle Mass and Strength, Obesity & Overweight | Not phased | Recruiting now | 60 |
| NCT07602699 | Multi-Site Trial of Tirzepatide for Smoking Cessation | Smoking Cessation, Smoking Behaviors | Phase 2 | Recruiting now | 300 |
| NCT07220473 | Tirzepatide to Slow Biological Aging | Aging, LONGEVITY 1 | Phase 2 | Recruiting now | 90 |
| NCT07633639 | GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | Obesity | Not phased | Recruiting now | 200 |
| NCT05822544 | Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes | Healthy Subjects, Obesity | Phase 1 | Recruiting now | 564 |
| NCT07091734 | Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024 | Lipodystrophy, Partial | Phase 2 | Recruiting now | 32 |
| NCT07382024 | Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation | Atrial Fibrillation Ablation, Persistent Atrial Fibrillation | Not phased | Not yet recruiting | 200 |
| NCT07218445 | The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity | Obesity, Menopause Hot Flashes | Phase 4 | Recruiting now | 40 |
| NCT07284511 | A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar | Type 1 Diabetes, Type 1 Diabetes Mellitus | Phase 3 | Recruiting now | 105 |
| NCT07588438 | Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | Obesity, Diabetes Mellitus, Type 2 | Phase 4 | Recruiting now | 160 |
| NCT07619989 | Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists | Obesity & Overweight | Not phased | Recruiting now | 24 |
| NCT07349641 | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | Phase 2 | Not yet recruiting | 55 |
| NCT07107334 | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | Endometrioid Endometrial Adenocarcinoma | Phase 2 | Recruiting now | 20 |
| NCT07438444 | A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | Diabetes Mellitus, Type 2, Obesity | Phase 4 | Recruiting now | 344 |
| NCT06575738 | Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents | Obesity, Adolescent Obesity | Phase 1 | Recruiting now | 40 |
| NCT07027969 | Metabolic Surgery for Atrial Fibrillation Elimination | Atrial Fibrillation, Obesity and Obesity-related Medical Conditions | Phase 4 | Not yet recruiting | 100 |
| NCT07244445 | Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy | Dietary Change, Obesity & Overweight | Not phased | Recruiting now | 108 |
| NCT07693608 | An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder | Obesity, Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | 45 |
| NCT07483801 | DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | Cardiovascular Diseases | Phase 4 | Not yet recruiting | 112 |
| NCT07226947 | Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment | Obesity, Body Composition | Not phased | Recruiting now | 100 |
| NCT06847399 | Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder | Obesity and Overweight, Binge Eating Disorder | Phase 2 | Recruiting now | 105 |
| NCT07354880 | Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease | Obesity & Overweight, Adult Congenital Heart Disease | Phase 4 | Not yet recruiting | 30 |
| NCT07443956 | Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis | Psoriatic Arthritis (PsA), Obesity & Overweight | Not phased | Recruiting now | 45 |
| NCT06727331 | Study of Tirzepatide for Recovery and Alcohol Use Management | Alcohol Use Disorder (AUD) | Phase 2 | Recruiting now | 20 |
| NCT07574723 | Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity | Obesity | Not phased | Recruiting now | 68 |
| NCT07244458 | Dietary Peanuts and Nutrition-Related Outcomes | Dietary Change, Obesity & Overweight | Not phased | Recruiting now | 64 |
| NCT07373834 | Tirzepatide and Muscle Outcomes in Obesity | Obesity (Disorder) | Not phased | Recruiting now | 30 |
| NCT07058155 | Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease | Liver Cirrhoses, Portal Hypertension Related to Cirrhosis | Phase 4 | Recruiting now | 70 |
| NCT07715929 | Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients | Atrial Fibrillation, Obesity & Overweight | Phase 4 | Not yet recruiting | 710 |
| NCT07605247 | Tirzepatide in the Treatment of Endometrial Cancer | Endometrial Cancer | Phase 2 | Not yet recruiting | 30 |
| NCT07319975 | Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity | Obesity | Not phased | Not yet recruiting | 48 |
| NCT06901245 | Tirzepatide in PWS, HO and GNSO | Prader-Willi Syndrome, Hypothalamic Obesity | Phase 4 | Recruiting now | 36 |
| NCT06790225 | Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA) | Bone Disease, Metabolic, Diabetes Mellitus, Type 2 | Not phased | Recruiting now | 12 |
| NCT07293325 | Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | Adults With Simple Obesity | Not phased | Recruiting now | 66 |
| NCT07213323 | Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment | Obesity &Amp; Overweight, Digestive Disorders | Not phased | Not yet recruiting | 50 |
| NCT06657209 | Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide | Diabetes Mellitus, Type 2, Diabetes | Phase 4 | Recruiting now | 104 |
| NCT06582875 | Glucagon-Like Peptide-1 Receptor Agonist in ADPKD | Autosomal Dominant Polycystic Kidney, Obesity | Phase 2 | Recruiting now | 126 |
| NCT06802081 | TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation | Atrial Fibrillation, Obesity | Phase 2 | Recruiting now | 100 |
| NCT07326111 | A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese | Polycystic Ovary Syndrome (PCOS), Obesity & Overweight | Phase 4 | Recruiting now | 198 |
| NCT07387796 | Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation | Drug Discontinuation, Substance Use Disorders | Not phased | Recruiting now | 40 |
| NCT05912621 | Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity | Obesity, Overweight and Obesity | Phase 2 | Recruiting now | 66 |
| NCT06857942 | A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Psoriasis, Overweight or Obesity | Phase 4 | Recruiting now | 200 |
| NCT07697391 | AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes | Obesity, Diabetes Mellitus, Type 2 | Phase 4 | Not yet recruiting | 285 |
| NCT06734312 | MAINTAIN (Mucosal AblatIoN Therapy After INcretins) | Obesity and Obesity-related Medical Conditions, Obesity and Overweight | Not phased | Recruiting now | 20 |
| NCT07202247 | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Recruiting now | 60 |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Metabolic Dysfunction-Associated Steatotic Liver Disease | Phase 3 | Recruiting now | 4500 |
| NCT06180616 | Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity | Type 1 Diabetes Mellitus, Overweight and Obesity | Phase 2 | Not yet recruiting | 40 |
| NCT07481747 | Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | Phase 3 | Recruiting now | 2539 |
| NCT06630585 | GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes | Type 1 Diabetes (T1D) | Phase 3 | Recruiting now | 42 |
| NCT07364175 | A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults | Hypertension, Obesity & Overweight | Not phased | Recruiting now | 60 |
| NCT06911203 | A Study of BGM0504 in Participants With Obesity | Obesity | Phase 2 | Recruiting now | 90 |
| NCT07065552 | Tirzepatide in Obesity-Driven Endometrial Cancer | Endometrial Cancer, Obesity | Phase 1 | Recruiting now | 20 |
| NCT06700538 | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Obesity | Phase 2 | Recruiting now | 180 |
| NCT07191873 | Tirzepatide in Idiopathic Intracranial Hypertension Trial | Idiopathic Intracranial Hypertension (IIH) | Phase 4 | Not yet recruiting | 60 |
| NCT07635953 | New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes | Diabetes Mellitus | Phase 3 | Not yet recruiting | 296 |
| NCT07555730 | AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) | Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance | Phase 4 | Not yet recruiting | 400 |
| NCT06937086 | Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Ulcerative Colitis, Obesity or Overweight | Phase 3 | Recruiting now | 350 |
| NCT07676331 | Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial | Hormone-receptor-positive Breast Cancer, Early Breast Cancer | Phase 2 | Not yet recruiting | 168 |
| NCT06721507 | 2024 Tirzepatide-Bariatric Surgery | Obesity and Obesity-related Medical Conditions, Bariatric Surgery | Phase 4 | Recruiting now | 50 |
| NCT07559500 | Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | Alcohol Use Disorder (AUD) | Phase 1 | Recruiting now | 176 |
| NCT07463846 | A Study to Evaluate ALN-2232 in Participants With Obesity | Obesity | Phase 2 | Recruiting now | 156 |
| NCT06751589 | A Study of a Weight Loss Intervention in People With Endometrial Cancer | Endometrial Cancer | Phase 1 | Recruiting now | 36 |
| NCT05933499 | Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity | Obesity | Phase 2 | Recruiting now | 63 |
| NCT06732245 | Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | Obesity and Overweight | Phase 2 | Not yet recruiting | 224 |
| NCT06759701 | Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | Diabetes, Prostate Cancer | Phase 1 | Recruiting now | 30 |
| NCT06374875 | Fibrosis Lessens After Metabolic Surgery | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease | Phase 4 | Recruiting now | 120 |
| NCT06073184 | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium | Endometrial Cancer, Atypical Hyperplasia | Phase 2 | Not yet recruiting | 71 |
| NCT07292519 | Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) | Alcohol Use Disorder (AUD), Overweight or Obese | Phase 2 | Not yet recruiting | 46 |
| NCT07257484 | Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | Obesity (Disorder), Breast Cancer | Phase 4 | Recruiting now | 30 |
| NCT07423247 | Tirzepatide (Spartina) in Obese Kidney Transplant Recipients | Tirzepatide | Phase 4 | Recruiting now | 30 |
| NCT06518837 | Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer | Phase 2 | Recruiting now | 40 |
| NCT07728318 | Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Not phased | Not yet recruiting | 52 |
| NCT07096908 | Tirzepatide Use in People With Obesity and Type 1 Diabetes | Type1diabetes, Obesity | Phase 4 | Recruiting now | 60 |
| NCT06373146 | A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Obesity | Phase 2 | Completed | 392 |
| NCT04847557 | A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 3 | Completed | 731 |
| NCT05177653 | Separate and Combined Extrapancreatic Effects of the Incretin Hormones | Pancreatectomy; Hyperglycemia | Not phased | Completed | 13 |
| NCT06605703 | A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) | Obesity, Overweight | Phase 4 | Completed | 226 |
| NCT05963022 | A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) | Type 2 Diabetes | Phase 3 | Completed | 206 |
| NCT04311424 | Study of Tirzepatide in Healthy Participants | Healthy | Phase 1 | Completed | 6 |
| NCT04004988 | A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants | Healthy | Phase 1 | Completed | 47 |
| NCT04093752 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) | Type 2 Diabetes | Phase 3 | Completed | 917 |
| NCT06131437 | A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | Obesity | Phase 3 | Completed | 809 |
| NCT03482024 | A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function | Renal Insufficiency, End Stage Renal Disease | Phase 1 | Completed | 45 |
| NCT06648031 | Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | Type2diabetes | Phase 1 | Completed | 148 |
| NCT03730662 | A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Type 2 Diabetes Mellitus | Phase 3 | Completed | 2002 |
| NCT04184622 | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | Overweight, Obesity | Phase 3 | Completed | 2539 |
| NCT03987919 | A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | Completed | 1879 |
| NCT07194317 | A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment | Obese Patients | Not phased | Completed | 64 |
| NCT06588296 | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Psoriatic Arthritis, Obesity | Phase 3 | Completed | 279 |
| NCT04844918 | A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease | Obesity | Phase 3 | Completed | 267 |
| NCT04235959 | A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | Phase 1 | Completed | 24 |
| NCT06533527 | Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Diabetes Mellitus, Type 2, Obesity | Phase 4 | Completed | 69 |
| NCT06635057 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan | Type 2 Diabetes | Phase 4 | Completed | 166 |
| NCT04172987 | A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants | Healthy | Phase 1 | Completed | 40 |
| NCT05260021 | A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both | Type2 Diabetes, Diabetes Mellitus | Phase 3 | Completed | 99 |
| NCT03375463 | A Study of Tirzepatide (LY3298176) in Healthy Participants | Healthy | Phase 1 | Completed | 52 |
| NCT06890611 | A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants | Healthy | Phase 1 | Completed | 125 |
| NCT04166773 | A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Phase 2 | Completed | 190 |
| NCT06326047 | A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | Completed | 299 |
| NCT06047548 | A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Overweight, Obesity | Phase 3 | Completed | 441 |
| NCT05078255 | The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes | Type 2 Diabetes, Obesity | Not phased | Completed | 61 |
| NCT06445075 | Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese | Overweight and Obesity | Phase 2 | Completed | 102 |
| NCT05691712 | A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes | Diabetes Type 2, Diabetes Mellitus | Phase 3 | Completed | 257 |
| NCT03951753 | A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | Phase 1 | Completed | 117 |
| NCT04311411 | A Study of Tirzepatide in Overweight and Very Overweight Participants | Obesity, Overweight | Phase 1 | Completed | 114 |
| NCT06895408 | Separate and Combined Extrapancreatic Effects of GIP and GLP-1 | Pancreatectomy; Hyperglycemia | Not phased | Completed | 12 |
| NCT06326060 | A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight | Obesity | Phase 2 | Completed | 354 |
| NCT04050670 | A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes | Healthy | Phase 1 | Completed | 54 |
| NCT03882970 | A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 3 | Completed | 1444 |
| NCT04081337 | A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide | Obesity | Phase 1 | Completed | 55 |
| NCT04657003 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | Type 2 Diabetes, Overweight | Phase 3 | Completed | 938 |
| NCT05696847 | A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity | Obesity | Phase 1 | Completed | 28 |
| NCT03940742 | A Study of Tirzepatide in Participants With Impaired Liver Function | Hepatic Insufficiency | Phase 1 | Completed | 32 |
| NCT04537923 | A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin | Type 2 Diabetes | Phase 3 | Completed | 1428 |
| NCT05412004 | Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Obstructive Sleep Apnea, Obesity | Phase 3 | Completed | 469 |
| NCT04039503 | A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin | Type 2 Diabetes | Phase 3 | Completed | 475 |
| NCT06400615 | Study That Tests AD109 in Patients Taking GLP-1 Drugs | OSA | Phase 2 | Completed | 40 |
| NCT06737042 | Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants | Obesity and Overweight | Phase 2 | Completed | 326 |
| NCT05706506 | A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) | Type 2 Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | Completed | 152 |
| NCT06935838 | Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV | Obesity and Overweight, HIV | Phase 2 | Completed | 12 |
| NCT06584916 | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | Obesity, Overweight | Phase 3 | Completed | 376 |
| NCT04050553 | A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2, Hypoglycemia | Phase 1 | Completed | 42 |
| NCT06221969 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Type 2 Diabetes | Phase 3 | Completed | 1024 |
| NCT04407234 | A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide | Overweight, Obesity | Phase 1 | Completed | 36 |
| NCT05564039 | A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) | Type 2 Diabetes | Phase 4 | Completed | 282 |
| NCT05024032 | A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) | Obesity, Overweight | Phase 3 | Completed | 210 |
| NCT05810597 | A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices | Healthy | Phase 1 | Completed | 65 |
| NCT04255433 | A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 3 | Completed | 13299 |
| NCT04657016 | A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program | Obesity, Overweight | Phase 3 | Completed | 579 |
| NCT05822830 | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Obesity, Overweight | Phase 3 | Completed | 751 |
| NCT05978713 | A Study of Tirzepatide (LY3298176) in Healthy Lactating Females | Healthy | Phase 1 | Completed | 11 |
| NCT06893211 | Effect of Tirzepatide on Brown Adipose Tissue in Obesity | Obesity | Phase 2 | Completed | 34 |
| NCT03861052 | A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | Completed | 636 |
| NCT06640972 | Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists | Triglycerides, Weight Gain Trajectory | Phase 2 | Completed | 68 |
| NCT06345066 | A Study of LY3841136 in Overweight and Obese Participants | Obesity, Overweight | Phase 1 | Completed | 96 |
| NCT06534411 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | Diabetes Mellitus, Type 2 | Phase 3 | Completed | 1023 |
| NCT06916065 | A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity | Overweight, Obesity | Phase 1 | Completed | 188 |
| NCT03861039 | A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 3 | Completed | 443 |
| NCT04660643 | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss | Obesity, Overweight | Phase 3 | Completed | 783 |
| NCT03954834 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Type 2 Diabetes Mellitus | Phase 3 | Completed | 478 |
| NCT06588283 | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Psoriasis, Obesity | Phase 3 | Completed | 281 |
| NCT03131687 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | Phase 2 | Completed | 318 |
| NCT07368855 | GLP-1 Medicines and Mental Health Changes | Obesity, Depression | Not phased | Completed | 90 |
| NCT03322631 | A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 1 | Completed | 48 |
| NCT02759107 | A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) | Healthy, Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | 142 |
| NCT05582096 | A Study of LY3457263 in Obese Participants | Overweight, Obesity | Phase 1 | Completed | 38 |
| NCT06297616 | A Study of LY3841136 in Japanese Participants With Obesity or Overweight | Obesity, Overweight | Phase 1 | Completed | 128 |
| NCT03311724 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 2 | Completed | 111 |
| NCT06803888 | Bariatric Surgery vs. Semaglutide vs. Tirzepatide | Obesity and Obesity-related Medical Conditions | Phase 4 | Running, closed to new participants | 125 |
| NCT06603571 | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Obesity, Overweight | Phase 2 | Running, closed to new participants | 367 |
| NCT05990374 | Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years | Diabetes | Not phased | Status not updated | 100 |
| NCT07154719 | GLP-1R Actions on Muscle and the Skeleton | Musculoskeletal Abnormalities, Obesity | Phase 4 | Running, closed to new participants | 50 |
| NCT06565611 | A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | Obesity | Phase 2 | Running, closed to new participants | 108 |
| NCT06861439 | GLP-1s to Enhance Lasting Optimal Weight | Obesity | Phase 4 | Running, closed to new participants | 40 |
| NCT06801015 | Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions | Obesity | Phase 4 | Running, closed to new participants | 30 |
| NCT07303556 | Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs | Heart Failure, Diabete Type 2 | Not phased | Running, closed to new participants | 120 |
| NCT06037252 | A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity | Type 2 Diabetes, Obesity | Phase 2 | Running, closed to new participants | 414 |
| NCT07685834 | Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss | Lax Skin | Not phased | Running, closed to new participants | 30 |
| NCT06301256 | Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa | Hidradenitis Suppurativa | Not phased | Status not updated | 20 |
| NCT06918405 | Efficacy and Safety of Tirzepatide for Weight Management | Obesity and Obesity-related Medical Conditions | Phase 3 | Running, closed to new participants | 440 |
| NCT05659368 | Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1 | Wolfram Syndrome | Phase 2 | Status not updated | 10 |
| NCT05536804 | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight, Obesity | Phase 2 | Running, closed to new participants | 140 |
| NCT06515418 | Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over | Obesity | Phase 2 | Stopped early | 204 |
| NCT06965413 | A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity | Obesity, Overweight | Phase 2 | Running, closed to new participants | 285 |
| NCT07299084 | A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2, Overweight | Phase 1 | Running, closed to new participants | 40 |
| NCT06914895 | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes, Obesity | Phase 3 | Running, closed to new participants | 905 |
| NCT06643728 | A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight | Obesity, Overweight | Phase 2 | Running, closed to new participants | 252 |
| NCT06662383 | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity | Phase 3 | Running, closed to new participants | 800 |
| NCT07128082 | The Long COVID Treatment Trial | Long COVID | Phase 2 | Running, closed to new participants | 1000 |
| NCT07057310 | Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Obesity, Menopause | Phase 4 | ENROLLING_BY_INVITATION | 30 |
| NCT06854614 | Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) | Obesity | Phase 4 | Running, closed to new participants | 150 |
| NCT05751720 | Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue | Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis | Phase 2 | Status not updated | 30 |
| NCT06901349 | A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes | Obesity, Overweight | Phase 2 | Withdrawn before enrolling | 0 — nobody enrolled |
| NCT06451458 | ECHO for Diabetes and Multiple Chronic Conditions Study | Diabetes Mellitus, Chronic Disease | Not phased | ENROLLING_BY_INVITATION | 20 |
| NCT05812183 | Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity | Dyspnea, Quality of Life | Phase 4 | Withdrawn before enrolling | 0 — nobody enrolled |
| NCT06075667 | A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity, Overweight | Phase 3 | Running, closed to new participants | 160 |
| NCT05556512 | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Obesity, Overweight | Phase 3 | Running, closed to new participants | 15374 |
| NCT06962280 | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes, Obesity | Phase 3 | Running, closed to new participants | 465 |
| NCT07707778 | Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV | Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease | Phase 4 | ENROLLING_BY_INVITATION | 60 |
| NCT06009653 | Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity | Obesity, Metabolic Disease | Phase 4 | Withdrawn before enrolling | 0 — nobody enrolled |
| NCT06745128 | Tirzepatide for Obesity and Meth Use Disorder | Obesity, Methamphetamine Use Disorder | Phase 2 | Running, closed to new participants | 45 |
| NCT06484114 | Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide | Obesity, Weight Change Trajectory | Not phased | Running, closed to new participants | 315 |
| NCT05433584 | A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 4 | Running, closed to new participants | 780 |
| NCT07000955 | Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Obesity | Phase 2 | Running, closed to new participants | 98 |
| NCT06162715 | GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | Severe Obesity, Obesity | Phase 3 | ENROLLING_BY_INVITATION | 30 |
—Read this
A trial count is not a verdict
These numbers describe how much has been formally studied in humans, not
whether something works or is safe for you. A compound can be tested for
one condition and sold for another — which is usually the story. This page
is automated aggregation from public registries; no physician has reviewed
it. Take anything here to a clinician.
Common questions about Tirzepatide
How many human trials does Tirzepatide have?
234. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.
Is Tirzepatide FDA approved?
Yes, but read the detail: FDA-approved for type 2 diabetes and chronic weight management. An approval for one condition is not an approval for everything it is marketed for.
What is Tirzepatide actually being tested for?
Registered studies cover: weight maintenance, obesity & overweight, obesity-related male infertility. Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.
Where does this data come from?
ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.
Get told when this changes
One email a week: what moved in the research, and which claims the record doesn't support. Free, and you can leave in one click.